Adverum Biotechnologies, Inc. ( NASDAQ: ADVM ) 26-Week Interim Analysis of the LUNA Phase 2 Trial Update Call July 17, 2024 8:00 AM ET Company Participants Mike Zanoni - Head of IR Laurent Fischer - President & CEO Charles Wykoff - Director of Research, Retina Consultants of Texas Conference Call Participants Joon Lee - Truist Securities Joseph Thome - TD Cowen Francois Brisebois - Oppenheimer Graig Suvannavejh - Mizuho Securities Luca Issi - RBC Capital Daniil Gataulin - Chardan Operator Hello, ladies and gentlemen. Thank you for standing by, and welcome to the Adverum's Webcast to discuss the 26-Week Interim Analysis of the ongoing LUNA Phase 2 trial that was presented earlier today at the 2024 ASRS Annual Meeting.
At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. As a reminder, today's call is being recorded.
It is now my pleasure to turn the floor over to Mike Zanoni, Adverum's Head of Investor Relations, who will make introductory comments. Mike Zanoni Thank you, operator. Good morning, and welcome, everyone.
Adverum recently issued a press release providing the details of the company's 26-week interim analysis of the ongoing LUNA Phase 2 trial. The press release is available in the Investor Relations section of the company's website at investors adverum.com.
Today's call will be led by Dr. Laurent Fischer, President and Chief Executive Officer. He'll be joined by Dr.
.
